News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MicroIslet Inc. (MII) Announces the Appointments of Dr. Christopher Marsh M.D., F.A.C.S., as Lead Transplant Advisor, and Dr. Ronald Goldblum, M.D., as Lead Clinical Development Consultant


1/28/2008 8:56:56 AM

SAN DIEGO--(BUSINESS WIRE)--MicroIslet Inc., (OTCBB: MIIS, http://www.microislet.com), the biotechnology company engaged in the development and commercialization of transplantation therapies for diabetes, announced that Dr. Christopher Marsh joined the Company’s Scientific Advisory Board and was named MicroIslet’s lead transplant consultant, and that Dr. Ronald Goldblum has been retained as the Company’s lead clinical development consultant.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES